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102Incidence and prognosis of vascular complications
after transcatheter aortic valve implantation
Bibombe P. Mwipatayi, MMed, FCS, FRACS,a,b Alarick Picardo, MBBS,a
Taolo Vijay Masilonyane-Jones, MBBS,a Robert Larbalestier, FRACS,c Shannon Thomas, FRACS,d
Jennifer Turner, RN,e Vikram Vijayan, MRCS, FRCS,a and Gerald Yong, FRACP, FSCAI,e Perth and
Randwick, Australia
Objective: Transcatheter aortic valve implantation (TAVI) has gained increasing global popularity as a minimally invasive
option for high-risk cardiac patients. However, this operation is not without risk, particularly of signiﬁcant vascular
complications that increase the morbidity, mortality, and overall cost of the procedure. We aim to present our experience
of TAVI-related vascular complications, including the morbidity and cost impacts of these events.
Methods: A case-series study was performed for all patients undergoing TAVI at our center. Vascular complications were
deﬁned according to the 2011 Valve Academic Research Consortium standardized end points. The data were prospec-
tively collected from February 2009 to April 2012, and the outcomes were entered into a database and cross-checked with
the hospital notes.
Results: TAVI was performed on 100 patients in our center during the study period, and the 30-day mortality was 6%.
Access approaches included 81 transfemoral, 18 transapical, and one trans-subclavian access. The average patient age was
84.9 years, and 65% of the patients were male. Among the transfemoral procedures, there were 16 vascular access-related
complications (VAC), including nine major and seven minor complications. The major complications included aortic
dissection, iliac arterial rupture, femoral dissection, false aneurysms, and distal embolization, all of which required
surgical or endovascular repair. An apical false aneurysm and an apical tear were major VAC of the transapical group, with
the latter resulting in death. Patients with VAC had higher blood transfusion requirements (4.1 6 4.5 units vs 0.9 6 2.2
units; P [ .004), greater length of hospital stay (16.4 6 10.7 days vs 6.5 6 5.1 days; P [ .001), and increased cost
(A$93,448 6 21,435 vs A$69,932 6 15,007; P[ .002) compared with the non-VAC group. The predictors of vascular
complications using multivariate analysis included European System for Cardiac Operative Risk Evaluation (odds ratio,
1.06; 95% conﬁdence interval, 1.02-1.10; P [ .001) and diabetes mellitus (odds ratio, 5.07; 95% conﬁdence interval,
1.17-21.88; P [ .03). Occurrence of major VAC did not affect in-hospital or 30-day mortality rates and was not
associated with poorer survival.
Conclusions: Vascular complications affect perioperative management and outcomes following TAVI. Our ﬁndings show
that these complications often require urgent surgical or endovascular repair and result in increased blood transfusions,
greater length of hospital stay, and signiﬁcantly increased costs. Diabetes mellitus and logistic European System for
Cardiac Operative Risk Evaluation may be predictive of VAC and should be considered during TAVI patient
selection. (J Vasc Surg 2013;58:1028-36.)Aortic stenosis (AS) is one of the most common cardiac
valve pathologies. The prevalence of AS increases with age
and population-based studies report a prevalence between
2.8% and 4.6% for patients over 75 years old.1 Surgical
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8therapy for AS. However, up to two-thirds of patients
with symptomatic AS are excluded from surgical interven-
tion secondary to high perioperative risk proﬁles.2
Since the ﬁrst-in-man procedure was performed in
2002,3 transcatheter aortic valve implantation (TAVI) has
been evolving. Published results now suggest mortality
rates similar to SAVR at 2 years for high-risk patients.4 In
patients not suitable for SAVR, TAVI has been reported
to reduce 2-year mortality and valve-related symptoms.5
Advances in assessment, materials, technique, and aftercare
have led to vast improvements in the provision of TAVI
programs worldwide over the past 10 years.
Several procedure-related pitfalls have been identiﬁed.
These include central and peripheral vascular complica-
tions, of which acute kidney injury, stroke, and access site
complications are the most widely recognized.6-8
The occurrence of vascular complications after TAVI is
associated with signiﬁcant morbidity and mortality that
increase the overall procedure cost. Precautions to avoid
complications entail a thorough vascular evaluation of
prospective TAVI patients. There is a high prevalence of
peripheral arterial disease in the elderly patients that
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anatomy is pertinent in evaluating the safety of large sheath
access, where current devices feature 18-26F (French size)
access sheaths. The risk of access site vascular injury and
distal plaque embolization must be evaluated before per-
forming the procedure. Alternative strategies must be
employed as necessary.8,11-14
In this study, we aim to determine the incidence,
implications, and determinants of vascular complications
following TAVI performed at a single center in Western
Australia.
METHODS
Patient population. Transcatheter aortic valve
implantation was initiated for high-risk AS patients as
a state-wide service based in Royal Perth Hospital, Western
Australia in 2009. Patients with symptomatic severe AS
were offered TAVI if they were considered to have a high
operative risk (generally deﬁned as age $80 years old and/
or logistic European System for Cardiac Operative Risk
Evaluation [EuroSCORE] $20%, or the presence of other
high-risk factors that are not included in the Euro
SCORE).15,16 All patients that were not candidates for
opened surgical repair were considered for TAVI and
included in our database. The EuroSCORE is a surgical
risk scoring system developed in 1999 from a multinational
European database. The model provides an estimate of
a patient’s anticipated 30-day mortality according to the
patient demographic characteristics, cardiovascular and
noncardiovascular risk factors, and procedural variables. A
multidisciplinary heart team, comprised of interventional
cardiologists, cardiothoracic surgeons, cardiac anesthetists,
and a vascular surgeon, were involved in the selection of all
patients. The leading interventional cardiologist performed
all TAVI procedures (G.Y.), and any potential vascular
problems were addressed or discussed with the leading
vascular surgeon (B.M.). Informed consent was obtained
from all patients (for the therapeutic procedure, clinical and
procedural data collection). The local ethical committee
approved the registry.
TAVI procedure and postprocedural monitoring.
Devices. Transfemoral TAVI was performed using either
a balloon-expandable Edwards SAPIEN (Edwards Life-
sciences, Irvine, Calif) or the self-expandable Medtronic
CoreValve (Medtronic CV, Irvine, Calif) prosthesis. The
balloon expandable valve required a 22-24F arterial sheath
in the earlier phase of the program before changing to an
18-19F arterial sheath. The self-expanding valve required
an 18F arterial sheath. A transapical approach (require up
to 26F arterial sheath) was available with the balloon
expandable valve, however, a trans-subclavian approach
was only available with the self-expanding valve.
Approach selection. Once a patient had been identi-
ﬁed as a TAVI candidate, the route of approach was deter-
mined as transfemoral, transapical, or trans-subclavian. No
evidence-based guidelines are available for this decision.
However, a number of criteria and parameters are reported
in the literature that might favor one approach over theother.17,18 For the transfemoral approach, a minimum
iliac-femoral diameter of 6-6.5 mm was required for an
18-19F sheath, and a minimum of 7-8 mm was needed for
a 22-24F sheath. Calciﬁcation, vessel tortuosity, aneurysms
of the abdominal aorta, plaque, and an unfolded or
tortuous aortic arch were considered when predicting the
success of device passage into the valve position. The
assessment of the diameter and the calciﬁcations and
tortuosity of the iliac arteries and of the aorta were evalu-
ated with invasive aortography and multislice computed
tomographic angiography. The transfemoral approach was
used as the ﬁrst choice unless contraindicated.
Procedure. Transfemoral TAVI was performed in the
coronary catheterization laboratory under ﬂuoroscopic
guidance. The procedural steps have been well described
previously.3-5 Percutaneous vascular closure using the
preclosure technique19 was used in all cases except one.
These devices included the Perclose ProGlide Suture-
Mediated Closure System (Abbott Vascular, Santa Clara,
Calif) or the ProStar XL Percutaneous Vascular Surgical
System (Abbott Vascular). Three ProGlide devices were
used for 22-24F sheath access (suture deployed at 2, 10,
and 12 o’clock), and one ProStar device was used for 18-
19F sheath access. An open common femoral artery
exposure was performed in one patient with an aortobife-
moral graft. In every case, access site hemostasis and distal
limb perfusion was conﬁrmed by angiography after com-
pletion of the procedure.
Data collection and study end points. The lead
interventional cardiologist prospectively collected all data.
Medical records and databases were reviewed, and the
following information was gathered: baseline characteris-
tics, periprocedural data, comorbidities, and laboratory
parameters (full blood count and renal function) before
and after the TAVI procedure.
The designated primary study end points were any
vascular complications. These were categorized in accor-
dance with the Valve Academic Research Consortium
(VARC) guidelines, which designate vascular access-related
complications (VAC) into major and minor complications.
The “access site” is deﬁned as any location (arterial or
venous) traversed by a guidewire, a catheter, or a sheath
(including the left ventricular apex and the aorta). The
term ‘access related’ is deﬁned as any adverse clinical conse-
quence possibly associated with the access sites used during
the procedure.13 The secondary study end points included
length of hospital stay, the incidence of life-threatening or
major bleeding, in-hospital mortality, and cumulative
mortality. Healthcare utilization was obtained in terms of
the total direct and indirect costs of the index hospitaliza-
tion using all the reports from the different cost centers
in the hospital. Any complications associated with the left
ventricle apex site during transapical TAVI were also re-
ported as an end point.
Statistical analysis. Categorical data were expressed
as the number of patients and percentage, whereas contin-
uous variables were expressed as the mean 6 standard
deviation (95% conﬁdence interval [CI]) or median with
Fig 1. Perth (Western Australia) transcatheter aortic valve implantation (TAVI) program. Flow chart showing the
patients who underwent TAVI on the basis of the Western Australian TAVI program at Royal Perth Hospital, Australia
from February 2009 to July 2012.
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dural characteristics, and outcome measures between
patients who experienced vascular complications and those
without vascular complications were compared with the use
of c2 test, Mann-Whitney test, and t-test. An estimation of
the cumulative mortality between the two groups of patients
was performed with the Kaplan-Meier method, and events
were compared by the log-rank test. A two-sided P value of
less than .05 was considered signiﬁcant.
The following variables were included in the model for
the prediction of vascular complications: sheath size, dia-
betes mellitus, coronary artery disease, cerebrovascular
disease, chronic obstructive pulmonary disease, hyperten-
sion, dyslipidemia, baseline estimated glomerular ﬁltration
rate, logistic regression model of EuroSCORE (logistic
EuroSCORE), body mass index, and hemoglobin. Univar-
iate logistic regression analyses were applied to identify
factors associated with overall vascular complications. A
multivariate stepwise logistic regression analysis that
included variables with P value<.1 in the univariate analysis
was used to determine the independent predictors of overall
vascular complications. The derived CI was subsequently
adjusted with a bootstrapping procedure to overcome the
potential model over-ﬁtting caused by the small number
of patients and outcome event. A receiver operating charac-
teristic curve was generated with all statistically signiﬁcant
variables, and the area under the curve did provide ameasure
of discrimination according to Hosmer and Lemershow
classiﬁcation. A negative binomial regression model was
used for modelling over dispersed count outcome variables.
Analyses were conducted using PASW 18 (SPSS, Chicago,
Ill) and STATA v. 12 (Stata Corp, College Station, Tex).RESULTS
In this study, 100 patients underwent TAVI at Royal
Perth Hospital between February 2009 and July 2012. A
transfemoral approach was used in 81 patients and a trans-
apical approach was used in 18 patients. One patient had
a trans-subclavian approach (Fig 1). The procedure was
successful in 98% of patients, and the 30-day mortality
rate was 6%. Two patients died within 24 hours of the
TAVI procedure. The ﬁrst patient had a low valve position
during the procedure associated with severe paravalvular
aortic regurgitation requiring a “valve-in-valve” bailout.
This resulted in an apical tear that could not be repaired
and resulted in death. The second patient developed severe
aortic regurgitation after balloon aortic valve replacement
resulting in severe compromise needing cardiopulmonary
resuscitation prior to successful implantation of the trans-
catheter heart valve. The resuscitation led to rib fracture
and liver laceration, which resulted in death.
Baseline and periprocedural characteristics. The
baseline patient characteristics and periprocedural charac-
teristics are summarized in Table I. The signiﬁcant risk
factors identiﬁed in the patients who had VAC were
coronary artery disease, previous myocardial infarction
and/or percutaneous coronary intervention, diabetes
mellitus, dyslipidemia, hypertension, and logistic Euro-
SCORE. Sheath size, valve size, porcelain aorta, and
vascular approach were not signiﬁcantly different between
patients with or without VAC.
Primary outcome. VAC occurred in 16% of patients
(n ¼ 16). These complications included common femoral
artery dissection (3), apical complications (2), access site
bleeding (1), false aneurysms (5), an iliac artery rupture
Table I. Baseline characteristics of the patients and periprocedural characteristics
Variables
All patients
(n ¼ 100)
Patients without
VAC (n ¼ 84)
Patients with
VAC (n ¼ 16) P value
Age, years 84.9 6 6 84. 8 6 6.3 85.1 6 .4.5 .85
Male sex, % 65 56 (66.7) 9 (56.2) .43
BMI, kg/m2 26 (IQR: 23.2-28.8) 26 (IQR: 23.3-28.8) 25 (IQR: 24-26.4) .57
Chronic kidney disease (eGFR < 60
mL/min per 1.73 m2), %
38 32 (38.1) 6 (37.5) .96
Coronary artery disease, % 67 65 (77.4) 2 .009
Previous myocardial infarction, % 33 32 1 .03
PCI, % 40 39 (46.4) 1 (6.2) .001
CABG, % 30 29 (34.5) 1 (6.2) .05
Cerebrovascular disease, % 29 27 (42.1) 2 (12.5) .12
Diabetes mellitus, % 36 21 (25) 11 (68.7) .002
Hypertension, % 57 56 1 .001
Dyslipidemia, % 53 52 1 .003
Chronic obstructive pulmonary
disease, %
20 18 (21.4) 2 (12.5) .09
Severe chronic obstructive
pulmonary disease, %
6 5 (5.9) 1 (6.2) .96
Logistic EuroSCOREa 17.9 (IQR: 9-23.8) 12.8 (IQR: 9-21.45) 23.6 (IQR: 18.7-42.45) .03
STSb 5.35 (IQR: 3.8-6.9) 5.63 (IQR: 3.6-7.1) 5.59 (IQR: 4-5.9) .49
Baseline laboratory parameters
Hemoglobin, g/L 120.2 6 15.4 120.8 6 15.9 118.3 6 16.9 .55
Serum creatinine, mmol/L 101.5 6 28.7 103.2 6 30.1 99.2 6 28.9 .59
eGFR (mL/min per 1.73 m2) 64.9 6 19.5 64.7 6 19.9 66.9 6 22.8 .96
Cardiac status
Mean LVEF, % 52.3 6 11.1 (27-79) 51.9 6 11.2 (27-79) 54.2 6 10.8 (30-72) .48
NYHA class $ III, % 93 77 (91.7) 16 (100) .59
Porcelain aorta, % 6 5 (5.9) 1 (6.2) .35
Periprocedural variables
Transfemoral approach, % 81 67 (79.8) 14 (87.5) .68
Sheath size 20.6 6 3.2 20.6 6 3.3 20.3 6 3.3 .91
Valve size 25.9 6 2.2 25.9 6 2.3 26.4 6 2.1 .44
BMI, Body mass index; CABG, coronary artery bypass graft; eGFR, estimated glomerular ﬁltration rate; EuroSCORE, European System for Cardiac Operative
Risk Evaluation; IQR, interquartile range; LVEF, left ventricular ejection fraction; NA, not applicable; NYHA, New York Heart Association; PCI, percu-
taneous coronary intervention; SD, standard deviation; STS, Society of Thoracic Surgeons; TAVI, transcatheter aortic valve implantation; VAC, vascular
access-related complications.
Values are means 6 SD. The signiﬁcant P values are highlighted in bold.
aThe logistic EuroSCORE that measures patient risk at the time of cardiovascular surgery is calculated with the use of a logistic-regression equation. Scores
range from 0% to 100%, with higher scores indicating greater risk. A logistic EuroSCORE higher than 20% indicates very high surgical risk.
bThe STS score measures patient risk at the time of cardiovascular surgery on a scale that ranges from 0% to 100%, with higher numbers indicating greater risk.
An STS score higher than 10% indicates very high surgical risk. Chronic kidney disease ¼ eGFR < 60 mL/min per 1.73 m2.
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(1), distal embolization (2), and a femoral AV ﬁstula
formation (1).
Major vascular complications occurred in nine patients
(9%), and endovascular (primarily by stenting using either
a cover stent in the common iliac arteries or self-
expansible stent in the external iliac and common femoral
arteries across the inguinal ligament) or open surgical repair
was required in all patients (Table II). The total VAC rate
was 20% in the ProStar group and 15% in ProGlide group.
The choice of closure device was not predictive of devel-
oping major vascular complications (odds ratio [OR],
0.2; 95% CI, 0.14-28.41; Pearson c2 test, P ¼ .60). Of
the nine major vascular complications, one patient died
within 30 days of the procedure. Most minor vascular
complications were managed conservatively. However,
a thrombin injection was administered for one patient
who developed a false aneurysm.Secondary outcome. Procedural outcomes and
mortality rates are recorded in Table III. The average
length of stay for all TAVI patients was 9.1 days. The
length of stay was signiﬁcantly higher in patients that had
vascular complications (16.4 6 10.7 days vs 6.5 6 5.1
days; P ¼ .001). Patients who developed vascular compli-
cations also had a longer high-dependency or coronary care
stay, although this difference was not statistically signiﬁcant
(8.1 days vs 4.0 days; P ¼ .08).
Patients with vascular complications had signiﬁcantly
more cases of major or life-threatening bleeding (50.0%
vs 7%; P ¼ .02) and subsequently received more transfused
units of packed red blood cells (4.1 units vs 0.9 units;
P ¼ .004).
There was no difference in the in-hospital or 30-day
mortality between patients with and without vascular
complications. Kaplan-Meier curves (Fig 2, A and B)
show that the survival rate was not statistically different
Table II. Vascular complications and management
Sheath size Access VAC VARC classiﬁcation Treatment Outcome
1 24F Preclose - ProGlide Femoral dissection Major Endovascular repair Satisfactory
2 26F Transapicala LV apical tear Major Surgical repair Death
3 24F Preclose - ProGlide Site bleeding Minor Conservative Satisfactory
4 18F Preclose - ProStar Femoral dissection Minor Conservative Satisfactory
5 26F Transapicala LV apical pseudoaneurysm Major Surgical repair Satisfactory
6 22F Preclose - ProStar False aneurysm Minor Thrombin injection Satisfactory
7 18F Preclose - ProStar False aneurysm Major Surgical repair Satisfactory
8 18F Preclose - ProStar Iliac rupture Major Endovascular repair Satisfactory
9 18F Preclose - ProStar External iliac dissection Minor Conservative Satisfactory
10 18F Preclose - ProStar Thoracic dissection and distal embolization Major Surgical repair Satisfactory
11 18F Preclose - ProStar Femoral dissection Minor Conservative Satisfactory
12 18F Preclose - ProStar Distal embolization Major Surgical repair Satisfactory
13 18F Preclose - ProStar False aneurysm Major Surgical repair Satisfactory
14 18F Preclose - ProStar False aneurysm Major Surgical repair Satisfactory
15 18 Fr Preclose - ProStar False aneurysm Minor Conservative Satisfactory
16 18F Preclose - ProStar Femoral AV ﬁstula Minor Conservative Satisfactory
AV, Arteriovenous; LV, left ventricle; VAC, vascular access-related complications; VARC, Valve Academic Research Consortium.
All cases with VAC.
aAnterolateral minithoracotomy approach.
Table III. Procedural and 30-day outcomes
Variables Whole cohort (n ¼ 100)
Patients with no VAC
(n ¼ 84)
Patients with VAC
(n ¼ 16) P value
Procedural variables
Procedure duration, minutes
(range)
106.2 6 43.4 (77.5-117.0) 103.4 6 46.7 (51.0-281.0) 115.1 6 31.6 (82.0-180.0) .32
Screening time, minutes
(range)
26.1 6 12.5 (17.5-29.6) 25.4 6 14.1 (8.2-72.0) 27.8 6 6.5 (14.3-39.3) .26
Volume contrast, mL (range) 221.8 6 124.6 (122.2-291.2) 223.1 6 129.7 (80.0-648.0) 218.1 6 112.3 (100.0-443.0) .23
Bleeding event and transfusion
30-days life-threatening/
major bleedinga
14 6 (7%) 8 (50%) .02
Number of units of packed
cells transfused
1.8 6 3.3 (0.0-15) 0.9 6 2.2 (0-12) 4.1 6 4.5 (0-15) .004
30-day minor/major strokea
Minor stroke 1 (1%) 1 (0.1%) 0 NA
Major stroke 0 0 0 NA
Cardiac/renal complicationsa
AKId 18 15 (17.8%) 3 (18.7%) .92
Periprocedural myocardial
infarctione
6 5 (5.9%) 1 (6.2%) .88
Length of hospital stay
LOS,b days 9.1 6 8.1 (1-30) 6.5 6 5.1 (1-23) 16.4 6 10.7 (1-30) .001
HDU/ICU, days 5.1 6 3.9 (32-24) 4 6 1.7 (2-9) 8.1 6 6.3 (3-24) .08
Mortalitya
30-day mortality 6 (5%) 5 (5.9%) 1 (6.3%) .96c
Cumulative mortality 17 (17%) 15 (17.8%) 2 (12.5%) .53c
AKI, Acute kidney injury; HDU, high-dependency unit; ICU, intensive care unit; LOS, length of stay; NA, not applicable; RIFLE, Risk, Injury, Failure, Loss,
and End-stage Kidney; SD, standard deviation; VAC, vascular access-related complications.
aValues are expressed as n (%), otherwise the value are expressed as mean 6 SD.
bTotal length of hospital stay including rehabilitation and ICU/HDU care periods.
cLog-rank test.
dAKI was deﬁned as change in serum creatinine (up to 72 hours) compared with baseline. AKI was classiﬁed in three stages according to the modiﬁed RIFLE
classiﬁcation. Only patients who develop stage 2 and 3 AKI were included in the analysis (Supplementary Table II, online only).
eClinical and/or biochemical evidence of myocardial infarction occurring #72 hours after the index procedure was deﬁned as periprocedural myocardial
infarction. Acute ischemic events occurring after 72 hours are considered spontaneous myocardial infarction.
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tions vs 87.5% in the VAC group; P ¼ .53) at 46 months
follow-up. A subsequent survival analysis between themajor and minor complication groups was not statistically
signiﬁcant (88.9% for the major VAC group vs 85.7% for
the minor VAC group; P ¼ .81).
Fig 2. A, Kaplan-Meier curves of survival at 1400 days follow-up
for the entire population for patients who underwent transcatheter
aortic valve implantation (TAVI) with vascular complications and
no vascular complications. The overall survival rate of all patients
was 83%, with 82.1% for the no vascular access-related complica-
tion (VAC) group and 87.5% for the VAC group at 46 months
follow-up. B, Kaplan-Meier curves of survival at 1400 days follow-
up for the patients who underwent TAVI with major VAC, minor
VAC, and no VAC. The overall survival rate of all patients was 83%,
with 82.1% for the no VAC group, 88.9% for the major VAC
group, and 85.7% for the minor VAC group at 46 months follow-
up. SE, Standard error.
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and without vascular complications during TAVI. Vascular
complications resulted in a statistically signiﬁcant cost
increase (P < .05) attributable to high-dependency/coronary care bed costs, medical personnel, pharmacy
services, allied health service costs, laboratory and radiology
costs, and the costs of ward consumables and sundries. The
total gross additional mean cost incurred with a vascular
complication was A$23,526, which equated to a 33.6%
mean cost increase per VAC case (P ¼ .002).
Predictors of vascular complications. Using logistic
univariate regression analysis, VAC was associated with
coronary artery disease (OR, 0.04; 95% CI, 0.01- 0.20;
P ¼ .009), previous myocardial infarction (OR, 0.11;
95% CI, 0.01-0.86; P ¼ .03), and previous percutaneous
coronary intervention (OR, 0.36; 95% CI, 0.21-0.64;
P ¼ .001). Additionally, a history of cardiac surgery (OR,
0.12; 95% CI, 0.01-1.01; P ¼ .05), diabetes mellitus
(OR, 6.6; 95% CI, 2.05-21.19; P ¼ .002), logistic Euro-
SCORE (OR, 1.07; 95% CI, 1.03-1.11; P ¼ .03), hyper-
tension (OR, 0.03; 95% CI, 0.004-0.265; P ¼ .001), and
dyslipidemia (OR, 0.04; 95% CI, 0.01-0.32; P ¼ .003)
were associated with VAC. The only independent risk
factors identiﬁed to predict vascular complications using
a multivariate stepwise logistic regression analysis (Table V;
Fig 3) were diabetes mellitus (OR, 5.07; 95% CI, 1.17-
21.88; P ¼ .03) and logistic EuroSCORE (OR, 1.06; 95%
CI, 1.02-1.10; P ¼ .001). The occurrence of vascular
complication rate was not statistically related to the sheath
size used, ranging from 18F to 24F sheath for transfemoral
approach and up to 26F for transapical route (mean size of
sheath used between no VAC patients of 20.6F 6 3.3 vs
VAC patients of 20.3F 6 3.3; P ¼ .91) (Table II).
Using the negative binomial regression models with or
without reporting the incidence rate ratios (IRR), the im-
pact of vascular complications on total length of hospital
stay (IRR, 2.78; 95% CI, 1.94-3.96; P < .05), units
of blood transfusion (IRR, 4.54; 95% CI, 1.63-12.62;
P ¼ .004), and bleeding (OR, 6.64; 95% CI, 2.06-21.32;
P ¼ .001) was established.DISCUSSION
TAVI is rapidly evolving to become the standard of
care for patients with severe AS unsuitable or at severe
risk for surgical AVR. Vascular complications are a cause
for morbidity and mortality and, thus, remain an important
determinant of TAVI outcomes. This study demonstrates
that major vascular complications occur at a signiﬁcant
rate, often requiring surgical intervention, which leads to
an overall prolonged length of hospital stay, increased
blood transfusion requirements, and increased cost and
resource utilization. Diabetes mellitus and a high preoper-
ative logistic EuroSCORE (Supplementary Table I,
online only) independently predict vascular complications
in this cohort. From our overall learning curve of this
procedure, it is crucial to interrogate the aortoiliac and
femoral segments preoperatively appropriately to exclude
heavily calciﬁed, mostly circumferential calciﬁcations asso-
ciated with signiﬁcant luminal reduction. Any evidence of
infragenicular peripheral vascular disease should be noted
and well recorded.
Table IV. Breakdown of resource usage and costsa (2009-2012 Australian dollar) during the procedural hospitalization
according to the occurrence of vascular complications
Cost per patient, mean 6 SD
Mean cost difference (95% CI)Patients with no VACb (n ¼ 84) Patients with VAC (n ¼ 16)
Procedures 33,454 6 4074 34,554 6 4362 1100 (1201 to 4095)f
HDCc 12,200 6 2005 19,210 6 2418 7010 (2365-16,543)e
Medical personnel 3776 6 1006 8058 6 1677 4282 (3214-7868)e
Nursing staff 3744 6 875 4775 6 1194 1031 (867-3987)f
Allied health services 214 6 91 728 6 161 514 (65 to 710)e
Laboratory services 606 6 182 1156 6 242 550 (58-1065)e
Radiology services 1284 6 134 1893 6 204 609 (209-1768)e
Pharmacy services 4798 6 609 8070 6 1255 3272 (1876-7899)e
Ward consumables and others expensesd 9856 6 1863 15,004 6 2826 5148 (1768-13,284)e
Total 69,932 6 15,007 93,448 6 21,435 23,516 (18,345-27,890)g
CCU, Coronary care unit; CI, conﬁdence interval; HDC, high-dependency care; SD, standard deviation; VAC, vascular access-related complications.
aAdjusted costs.
bAll vascular complications.
cHDC and CCU cost.
dAdministrative, hardware depreciation, and operating theatre costs.
eP < .05.
fP > .05.
gP of the total cost was .002.
Table V. Multivariate stepwise logistic regression
analysis of variables associated with vascular complications
Variable Coefﬁcient OR (95% CI) SEa P value
Logistic EuroSCORE 3.27 1.06 (1.02-1.10) 0.02 .001
Diabetes mellitus 2.18 5.07 (1.17-21.88) 3.78 .03
Intercept 4.67 0.02 (0.01-0.11) 0.02 <.05
CI, Conﬁdence interval; EuroSCORE, European System for Cardiac
Operative Risk Evaluation; OR, odds ratio; SE, standard error; TAVI,
transcatheter aortic valve implantation.
Patients with diabetes mellitus that underwent TAVI are ﬁve times more
likely to sustain vascular complication than those who do not have diabetes
mellitus.
aThe derived SE was adjusted with bootstrapping procedure.
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Fig 3. Logistic model for vascular access-related complications
(VAC) with receiver operating characteristic (ROC) curve. Using
predicted probabilities for factors that predict strongly vascular
complication occurrence after transcatheter aortic valve implanta-
tion (TAVI), we can draw the ROC curve. The area under the
ROC curve is nearly 0.82; this is considered to have an excellent
discrimination for these two factors to predict VAC after TAVI.
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VARC guidelines, have been reported for other TAVI
series. These rates range from 9.5% to 51.6% with associ-
ated two- to threefold increases in 30-day mortality.15,20
Our study identiﬁed several important ﬁndings that
warrant discussion. We have consolidated current reports
of the advances in equipment and methods and demon-
strate that vascular complication rates are decreasing, and
TAVI can be performed with relative safety in high-risk
patients. In 100 patients, we reported major and minor
vascular complication rates of 9% and 7%, respectively.
This ﬁnding is comparable with the recent meta-analysis
of VARC clinical outcomes that consolidated 3519 patients
from 16 studies and reported a pooled estimated major,
minor, and total vascular complication rate of 11.9%,
9.7%, and 18.8%, respectively.20
Consistent with other published studies, we found that
patients with VAC had a signiﬁcantly higher risk of life-
threatening or major bleeding within 30 days. These
patients subsequently required a signiﬁcantly highernumber of blood transfusions. Although multiple pub-
lished reports have shown an increased rate of 30-day
mortality associated with major vascular complications,20-22
we have failed to demonstrate this association. Addition-
ally, we did not identify decreased long-term survival in
patients with VAC. We did not demonstrate any difference
in acute kidney injury and postprocedural myocardial
infarction between the two groups (Table III;
Supplementary Table II, online only).
Several reports on TAVI-associated vascular complica-
tions have been published over the past few years to inves-
tigate causes and risk factors for vascular complications.
Sheath to femoral artery ratio (SFAR), early center
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Volume 58, Number 4 Mwipatayi et al 1035experience, femoral artery calcium score, sheath diameter,
peripheral artery disease, and female sex have all been re-
ported as predictors for vascular complications.20,21
However, the only independent predictors for VAC
currently identiﬁed and reported are female sex and sheath
size. Genereux et al ﬁrst reported female gender as a signif-
icant predictor using results from the Placement of AoRTic
TraNscathetER Valve (PARTNER) trial (hazard ratio,
2.31; 95% CI, 1.08-4.98; P ¼ .03).23 These researchers
initially hypothesized that the smaller femoral artery diam-
eters in women with subsequent greater SFAR may be
a contributing factor. However, after adjusting for SFAR,
female sex was a strong independent predictor and suggests
the possibility of an intrinsic female predisposition to peri-
procedural complication with TAVI. Van Mieghem et al
recently also substantiated this ﬁnding by pooling the
TAVI databases of ﬁve European centers and evaluating
results from 986 patients who underwent transfemoral
TAVI. They reported both female sex (OR, 1.63; 95%
CI, 1.12-2.36) and the use of a >19F system (OR, 2.87;
95% CI, 1.68-4.91) as independent predictors for major
vascular complications.14,24
In our study, we identiﬁed seven factors that were asso-
ciated with an increased risk of vascular complications:
coronary artery disease, previous percutaneous coronary
infarction, previous myocardial infarction, dyslipidemia,
hypertension, and the logistic EuroSCORE. Interestingly,
our multivariate analysis identiﬁed two independent predic-
tors of vascular complication: logistic EuroSCORE (OR,
1.06; 95% CI, 1.02-1.10; P ¼ .001) and diabetes mellitus
status (OR, 5.07; 95% CI, 1.17-21.88; P ¼ .03)
(Table IV). The use of logistic EuroSCORE as an indepen-
dent predictor is suggestive of higher VAC risk in high-risk
patients, presumably because of comorbidities. However,
further research to corroborate and investigate this ﬁnding
is warranted. Notably, we did not identify sex as having any
inﬂuence on vascular complications.
While the risk factors we identiﬁed and those previously
published are reasonably common in the TAVI patient
population and therefore may be overlooked, operator
knowledge of this increased risk should generate extra vigi-
lance of the potential to cause injury, as the additional
costs, morbidity, and resource usage associated with VAC
is substantial.
In our study, the total mean cost was signiﬁcantly higher
in patients who sustained vascular complications (mean cost
difference: A$23,516; P ¼ .002). This additional cost was
signiﬁcant across nearly all sectors (Table V). Most of the
additional cost differences resulted from high dependency,
coronary care costs, and overall ward costs. The increased
length of stay due to complications (16.4 days vs 6.5 days;
P ¼ .001) was certainly a major contributor to this addi-
tional ward cost and resource usage. To the best of our
knowledge, this study is the ﬁrst that has reported the cost
and resource management associated with vascular compli-
cations. While Reinhol et al reported a 19.1% increase in
costs associated with major bleeding complications
following transfemoral TAVI (mean gross increase ¼V6426 [zA$8150]),25 our cost analysis has revealed
amean 33.6% cost increase incurred from vascular complica-
tions. A comparison of our baseline costs with Reinhol’s
publication indicates that our baseline costs are considerably
higher. However, in the PARTNER trial, Reynolds et al
have reported the mean total index admission costs for
TAVI via the transfemoral approach to be $73,219, which
is similar to our baseline cost (A$69,932).26,27 Nonetheless,
our study emphasizes that the additional cost and resource
usage associated with VAC is signiﬁcant, and care should
be taken to minimize this expenditure. Our cost analysis
included both major and minor vascular complications
collectively. Therefore, we anticipate that the cost increase
from only major VAC to be even greater.
The current study has several limitations. Although this
registry had limited and strict inclusion/exclusion criteria,
all patients included were initially suitable for endovascular
repair of severe AS. This patient selection may have led to
a selection bias of some patients who may have been suit-
able for open cardiac surgery. Moreover, the current data
analyses are retrospective, despite being derived from
prospectively collected data.
CONCLUSIONS
Vascular complications affect perioperative manage-
ment and outcomes in TAVI. Vascular complications may
require surgical repair and lead to prolonged hospital
stay, increased overall cost, and greater resource utilization.
Speciﬁc parameters, including type II diabetes status and
logistic EuroSCORE, may be predictive of which patients
will develop complications. These parameters should be
used to guide patient selection for this procedure.AUTHOR CONTRIBUTIONS
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Supplementary Table I (online only). Risk factors, deﬁnitions, and weights in standard (score) and logistic
(ß coefﬁcient) EuroSCORE Model (www.euroscore.org)
Risk factors Deﬁnition Score ß coefﬁcient
Patient-related factors
Age Per 5 years or part thereof over 60 years for standard
EuroSCORE and continuous for logistic EuroSCORE
1 0.0666354
Sex Female 1 0.3304052
Chronic obstructive pulmonary disease Long-term use of bronchodilators or steroids for lung disease 1 0.4931341
Extracardiac arteriopathy Any one or more of the following: claudication, carotid
occlusion or >50% stenosis, previous or planned
intervention on the abdominal aorta, limb arteries or
carotids
2 0.6558917
Neurological dysfunction disease Disease severely affecting ambulation or day-to-day
functioning
2 0.841626
Previous cardiac surgery Requiring opening of the pericardium 3 1.002625
Serum creatinine >200 m micromol/L preoperatively 2 0.6521653
Active endocarditis Patient still under antibiotic treatment for endocarditis at the
time of surgery
3 1.101265
Critical preoperative state Any one or more of the following: VT or VF or aborted
sudden death, preoperative cardiac massage, preoperative
ventilation before arrival in the anesthetic room,
preoperative inotropic support, intra-aortic balloon
counter-pulsation or preoperative ARF (anuria or
oliguria <10 mL/h)
3 0.9058132
Cardiac-related factors
Unstable angina Rest angina requiring i.v. nitrates until arrival in the
anesthetic room
2 0.5677075
Left ventricular dysfunction Moderate or LVEF z 30%-50% 1 0.4191643
Left ventricular dysfunction Poor or LVEF <30 % 3 1.094443
Recent myocardial infarction (<90 days) 2 0.5460218
Pulmonary hypertension Systolic pulmonary pressure >60 mm Hg 2 0.7676924
Operation-related factors
Emergent operation Carried out on referral before the beginning of the next
working day
2 0.7127953
Other than isolated CABG Major cardiac procedure other than or in addition to CABG 2 0.5420364
Surgery on thoracic aorta For disorder of ascending arch or descending aorta 3 1.159787
Postinfarct septal rupture Postinfarct septal rupture 4 1.462009
Constant ß0 Only for logistic EuroSCORE d 4.789594
ARF, Acute renal failure; CABG, coronary artery bypass graft; EuroSCORE, European System for Cardiac Operative Risk Evaluation; LVEF, left ventricular
ejection; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
The EuroSCORE has been developed for the prediction of in-hospital mortality after adult cardiac surgery. The standard EuroSCORE system consists of three
risk groups: low risk (0-2) with an expected mortality under 2%; medium risk (3-5) with an expected mortality under 5%; and high risk ($6) with an expected
mortality greater than 10%, but logistic EuroSCORE system tends to be more accurate in high-risk patients. The logistic EuroSCORE uses the same risk
factors as the additive EuroSCORE to produce preoperative mortality risk via a logistic regression calculation and can be achieved with the following formula:
Predicted mortality ¼ eðboþabi XiÞ=1þ eðboþabi XiÞ
Where
e is the natural logarithm ¼ 2.718281828.
bo is the constant of the logistic regression equation ¼ 4.789594.
bi is the coefﬁcient of the variable Xi in the logistic regression equation provided in the table below.
Xi ¼ 1 if a categorical risk factor is present and 0 if it is absent.
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Volume 58, Number 4 Mwipatayi et al 1036.e1Supplementary Table II (online only). Acute kidney injury (modiﬁed RIFLE classiﬁcation)
Stage 1 Increase in serum creatinine to 150%-200% (1.5-2.0  increase compared with baseline) or increase of $0.3 mg/dL
($26.4 mmol/L)
Stage 2 Increase in serum creatinine to 200%-300% (2.0-3.0  increase compared with baseline) or increase between >0.3 mg/dL
(>26.4 mmol/L) and <4.0 mg/dL (<354 mmol/L)
Stage 3a Increase in serum creatinine to $300% (>3  increase compared with baseline) or serum creatinine of $4.0 mg/dL
($354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L)
AKI, Acute kidney injury; RIFLE, Risk, Injury, Failure, Loss, and End-stage Kidney.
AKI was classiﬁed in three stages according to the modiﬁed RIFLE classiﬁcation. Of clinical signiﬁcance only stage 2 and 3 of AKI should be recorded to assess
patient renal.
aPatients receiving renal replacement therapy are considered to meet stage 3 criteria irrespective of other criteria.
